Business Wire

CELONIS

29.11.2021 09:55:13 CET | Business Wire | Press release

Share
Celonis Accelerates its Process Mining and Execution Management Leadership in India

Celonis , the global leader in execution management, today announced that it will expand its process mining and execution management operations into India. Celonis believes the opportunity for customers, global system integrators (GSIs), business process outsourcing (BPO) providers, consultants, and academics is as big as the shift from on-prem to cloud.

As part of its execution management initiative in India, Celonis has committed to investing over $100 million dollars into the Indian process industry and expects to create more than 1,000 jobs. The expansion into India enables the world’s leading business process professionals and experts to unlock billions in new process and execution value for both their customers and within their own companies. The Celonis execution management initiative was launched at a multi-day press conference and partner ecosystem event in Bangalore, India.

The opportunity for process mining and execution management in India is immense. To provide context, Everest Group reports that the India BPO market for financial services alone has the potential to grow from $18 billion to $250 billion and currently represents nearly half of the world’s global outsourcing market. Furthermore, IDC estimates that the Indian IT & Business Services1 market will grow from $7 billion to $20 billion by 2025.

“Process mining should be at the core of digital transformation efforts and can play a critical role in helping to achieve greater scale, agility, and business value realization,” said Amardeep Modi, Vice President, Everest Group. “Celonis partners and customers in India will likely benefit greatly by having this new hub to assist, train, and promote best practices for the region. It would also help tap into India’s large talent base to fulfil the fast-growing demand for process mining skills globally.”

“India is undeniably a top global talent hub, and an IT and operations stronghold for Global 2000 enterprises,” said Reetika Fleming, Research Leader at HFS Research. “With this investment, Celonis is taking its technology right where it is needed. This will make it much easier for service providers to develop data-proficient workforces and presents an exciting opportunity for Indian students and consultants to work with process intelligence technologies.”

The Celonis India execution management initiative is designed around three strategic pillars that will enable the entire India process industry, and eventually every company across all sectors, to immediately adopt the most state of the art technologies into their core operations:

  • Execution Management Without Limits : The first pillar of this initiative is the rollout of the Celonis Execution Management Without Limits and the Celonis for BPO programs. These industry-first programs allow unlimited access to Celonis process mining and execution management technologies to any BPO, GSI and consulting professional.
  • Celonis Academy : The second pillar of this initiative is to provide free training and access to the best-in-class methods, processes, and programs for process mining and execution management to the entire India process consulting industry. Celonis plans to initially train more than 100,000 consultants, students and academics in India. This program is part of a global initiative where Celonis will train more than 1 million experts on process mining and execution management.
  • Celonis Center of Excellence : The third pillar is the new Celonis Center of Excellence (CoE) which will be the one-stop shop for customers, partners and service providers in India. The CoE combines partner enablement support, professional services and value advisory for customers, a dedicated product engineering team, and a customer support team to provide around-the-clock expertise and innovation.

“Every significant process innovation wave, from client server, to the internet, to the cloud has gone through the heart of the India business process industry,” said Bastian Nominacher, co-CEO and co-founder of Celonis. “Celonis is honored to help drive the next generational shift in process modernization in India by embedding our state-of-the-art process mining and execution management technologies into the world’s leading BPO, GCC, GSI and consulting firms.”

The Celonis partner ecosystem already includes many of the top tier consultancies, business process outsourcing (BPO) providers and consulting firms around the world, such as Accenture , Cognizant , Deloitte , EY, Firstsource , HCL, IBM , Infosys , KPMG , PWC , TCS , Tech Mahindra , Wipro , WNS and more. All of whom use the Celonis EMS to power digital and process transformation initiatives - for themselves and their clients.

“Celonis has removed all barriers for the entire India process ecosystem to put data to work and arm companies and organizations in every industry with our Execution Management System - which our customers call the ‘process brain’ for their businesses,” said Malhar Kamdar, Chief Customer Officer for Celonis and Executive leader for India. “Celonis has fully opened our platform with the goal of unlocking billions of value for users, enterprises and society. We are thrilled to bring the power of data execution to all our customers and partners in India.”

"Celonis is a key partner for Bosch worldwide, as we work together to bring our software offerings and process analytics to the next level, required to foster our ambition to become a data-driven, leading AIoT company,” said Jens Bockholt, VP Regional Manager at Bosch. “We are delighted that Celonis is continuing their global expansion with a new Center of Excellence in India and we look forward to further collaborating and leveraging Celonis to better serve our customers. We believe this will be mutually beneficial for both Celonis and the growing Indian marketplace.”

At their 2021 World Tour, Celonis announced a series of investments across each of the three key imperatives of the Celonis Execution Management System (EMS) - data, intelligence and action. This included the acquisition of real-time streaming data technology Lenses.io; the launch of the Celonis Execution Graph, that connects events from different processes across the company to identify bottlenecks; and a planned market defining partnership with ServiceNow .

“India’s market and talent base represents an unparalleled opportunity to capitalize on the global adoption of process mining and execution management at a massive scale,” said Anitha Scaria George, VP and Head of Celonis India. “As with every movement, there are companies who trailblaze and leapfrog the competition, and those who find themselves at the back of the parade. Celonis will train the next generation of execution management leaders to apply data, intelligence, and action to every process, in every business, in every industry.”

About Celonis

Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.

© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners. 


1 tps://www.idc.com/getdoc.jsp?containerId=prAP48371321

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye